Combination of ranibizumab and navigated retinal photocoagulation in diabetic macular edema, compared to ranibizumab mono-therapy: Twelve month results

    loading  Checking for direct PDF access through Ovid



To evaluate the number of anti-VEGF injections needed in DME patients using a protocol with navigated laser


A consecutive series of 76 eyes with DME were included and randomized into 3 groups: 1. Ranibizumab monotherapy (n=27; using an observation and retreatment paradigm for anti-VEGF therapy that is compliant with the European Public Assessment Report (EPAR, European Medicines Agency) for ranibizumab), 2. Three consecutive monthly ranibizumab injections followed by navigated laser therapy, then application of the observation and retreatment paradigm as in group “1” (n=15), 3. Monthly ranibizumab injection until central retinal thickness (CRT) was reduced to 450μm (Spectralis OCT) then navigated laser therapy followed by the application of the observation and retreatment paradigm as in group “1” (n=34). Subjects were followed monthly (best corrected Visual acuity (BCVA), CRT) for 12month, to assess the number of anti-VEGF injections required to maintain stable clinical improvement.


After 12 month BCVA increased and in all three investigated groups significantly (group 1: 6.3 ±6.77; group 2: 7.1 ±8.22; group 3: 7.4 ±7.53 letters). To achieve these results, after an upload of three consecutive monthly applied ranibizumab injections, ranibizumab mono-therapy group (group 1) needed 5.2 ± 3.2 injections. In contrast, group 2 and 3 nedded significantly less ranibizumab injections (0.5 ± 0.8 and 0.8 ± 1.1, p<0.001).


Combining anti-VEGF with navigated laser showed similar visual improvements compared to anti-VEGF monotherapy with significantly fewer injections.


Commercial interest

Related Topics

    loading  Loading Related Articles